11 ESMO 2021 breakthroughs: practicing oncologist’s perceptions on data presentation

por van Halteren, H.K., Tan, A., Pellegrino, B., Brasiuniene, B., Bennouna, J., Cunquero-Tomás, A.J., Strijbos, M.
Publicado 2022

Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) i...

por Wekking, D., Porcu, M., Pellegrino, B., Lai, E., Mura, G., Denaro, N., Saba, L., Musolino, A., Scartozzi, M., Solinas, C.
Publicado 2023

Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review

por Pellegrino, B., Musolino, A., Llop-Guevara, A., Serra, V., De Silva, P., Hlavata, Z., Sangiolo, D., Willard-Gallo, K., Solinas, C.
Publicado 2020

1587P SARS-CoV-2 infection risk and COVID-19 prevalence in cancer patients during the first wave of COVID-19 pandemic in a Northern Italy’s virus epicenter area

por Musolino, A., Pellegrino, B., Isella, L., Tommasi, C., Pucci, F., Leonetti, A., Rapacchi, E., Leonardi, F., Bizzoco, S., Affanni, P., Veronesi, L., Sgargi, P., Maglietta, G., Michiara, M.
Publicado 2021

Mevalonate kinase deficiency: an early onset inflammatory bowel disease?

por Martins, A, Berrebi, D, De Lumley, L, Petit, B, Pellegrino, B, Arion, A, Jeanne-Pasquier, C, Lequerre, T, Pellier, I, Guillot, M, Faye, A, Goullet, O, Bader-Meunier, B, Melki, I
Publicado 2015

Twelve ESMO Congress 2022 breakthroughs: practicing oncologists’ perceptions and potential application on presented data

por van Halteren, H.K., Bennouna, J., Brasiuniene, B., Tomas, A. J. Cunquero, Trinidad, A. M. Garcia, Indini, A., Liposits, G., Pellegrino, B., Popovic, L., Tan, A., Vidra, R., Strijbos, M.
Publicado 2023

Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer

por Viansone, A., Pellegrino, B., Omarini, C., Pistelli, M., Boggiani, D., Sikokis, A., Uliana, V., Zanoni, D., Tommasi, C., Bortesi, B., Bonatti, F., Piacentini, F., Cortesi, L., Camisa, R., Sgargi, P., Michiara, M., Musolino, A.
Publicado 2022

Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical a...

por Pellegrino, B., Cavanna, L., Boggiani, D., Zamagni, C., Frassoldati, A., Schirone, A., Caldara, A., Rocca, A., Gori, S., Piacentini, F., Berardi, R., Brandes, A.A., Foglietta, J., Villa, F., Todeschini, R., Tognetto, M., Naldi, N., Bortesi, B., Montemurro, F., Ardizzoni, A., Boni, L., Musolino, A.
Publicado 2020

Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial

por Capoluongo, E.D., Pellegrino, B., Arenare, L., Califano, D., Scambia, G., Beltrame, L., Serra, V., Scaglione, G.L., Spina, A., Cecere, S.C., De Cecio, R., Normanno, N., Colombo, N., Lorusso, D., Russo, D., Nardelli, C., D’Incalci, M., Llop-Guevara, A., Pisano, C., Baldassarre, G., Mezzanzanica, D., Artioli, G., Setaro, M., Tasca, G., Roma, C., Campanini, N., Cinieri, S., Sergi, A., Musolino, A., Perrone, F., Chiodini, P., Marchini, S., Pignata, S.
Publicado 2022